Early AAV9-mediated SLC9A6 gene replacement preserves cerebellar structure and motor function in the shaker rat model of Christianson syndrome
- 1University of Sydney
Abstract
Christianson syndrome (CS) is an X-linked neurodevelopmental and neurodegenerative disorder caused by SLC9A6 loss of function, resulting in NHE6 deficiency and epilepsy, intellectual disability, cerebellar atrophy, and ataxia. Following on our prior gene replacement therapeutic development, we preclinically evaluated AAV9-mediated SLC9A6 gene replacement in the context of promoter selection, dosing, and treatment timing. Intracerebroventricular delivery of neuronal-targeted gene replacement at 1 x 10^11 vector genomes (vg) produced substantial improvements in motor coordination and preserved cerebellar volume, quantified through structural MRI. Early postnatal treatment prevented the development of gait ataxia throughout the longitudinal assessment period, statistically indistinguishable from wildtype controls, with molecular analyses demonstrating restored NHE6 expression and preservation of cerebellar markers. Interestingly, later treatments at timepoints corresponding to early neurodegenerative stages yielded strong initial effects, but these effects were largely lost over time, with half-life modelling demonstrating the need for early treatment. This conflicted with more persistent motor benefit shown in prior work with an engineered capsid, suggesting the need to consider the interaction between treatment timing and capsid-specific tropism and/or persistence. Finally, we built models capable of accurately predicting motor coordination from several protein markers. These findings will impact therapeutic development for CS, with relevance across neurodevelopmental genetic disorders.
Related
- LNP-mediated BCL11A Editing Corrects Sickling Phenotypes and Preserves HSPC Fitness Compared to Electroporation
- BNIP3L/NIX-mediated mitophagy limits Alzheimer disease pathology and preserves neuronal function
- Epigallocatechin-3-gallate attenuates PAR-2–mediated inflammatory signaling and preserves markers of mitochondrial integrity in osteoarthritic chondrocytes
- Longitudinal Impacts of Sex-Steroid Hormones on Cerebellar Structure in Adulthood are Sex Differentiated
- Longitudinal single-cell transcriptional profiling identifies dynamic neurodegenerative mechanisms in Christianson Syndrome rat
BibTeX
@misc{dahiya2026early,
title = {{Early AAV9-mediated SLC9A6 gene replacement preserves cerebellar structure and motor function in the shaker rat model of Christianson syndrome}},
author = {K. Dahiya and K. Sekaran and L. Hu and A. Bloomfield and E. Kapasakis and S. Henning-Smith and L. G. Riley and M. Evans and S. Haslam and J. Katakowski and D. N. Anderson and W. Gold and C. J. Anderson},
howpublished = {bioRxiv},
year = {2026},
month = nov,
doi = {10.64898/2026.11.04.764455},
url = {https://www.biorxiv.org/content/10.64898/2026.11.04.764455v1},
note = {CC BY-NC},
}
RIS
TY - UNPB
TI - Early AAV9-mediated SLC9A6 gene replacement preserves cerebellar structure and motor function in the shaker rat model of Christianson syndrome
AU - K. Dahiya
AU - K. Sekaran
AU - L. Hu
AU - A. Bloomfield
AU - E. Kapasakis
AU - S. Henning-Smith
AU - L. G. Riley
AU - M. Evans
AU - S. Haslam
AU - J. Katakowski
AU - D. N. Anderson
AU - W. Gold
AU - C. J. Anderson
PY - 2026
DA - 2026/11/04
PB - bioRxiv
DO - 10.64898/2026.11.04.764455
UR - https://www.biorxiv.org/content/10.64898/2026.11.04.764455v1
AB - Christianson syndrome (CS) is an X-linked neurodevelopmental and neurodegenerative disorder caused by SLC9A6 loss of function, resulting in NHE6 deficiency and epilepsy, intellectual disability, cerebellar atrophy, and ataxia. Following on our prior gene replacement therapeutic development, we preclinically evaluated AAV9-mediated SLC9A6 gene replacement in the context of promoter selection, dosing, and treatment timing. Intracerebroventricular delivery of neuronal-targeted gene replacement at 1 x 10^11 vector genomes (vg) produced substantial improvements in motor coordination and preserved cerebellar volume, quantified through structural MRI. Early postnatal treatment prevented the development of gait ataxia throughout the longitudinal assessment period, statistically indistinguishable from wildtype controls, with molecular analyses demonstrating restored NHE6 expression and preservation of cerebellar markers. Interestingly, later treatments at timepoints corresponding to early neurodegenerative stages yielded strong initial effects, but these effects were largely lost over time, with half-life modelling demonstrating the need for early treatment. This conflicted with more persistent motor benefit shown in prior work with an engineered capsid, suggesting the need to consider the interaction between treatment timing and capsid-specific tropism and/or persistence. Finally, we built models capable of accurately predicting motor coordination from several protein markers. These findings will impact therapeutic development for CS, with relevance across neurodevelopmental genetic disorders.
ER -